Founded on May 6, 2019 in Houston, Texas, Artemis DNA is a full service, Clinical Laboratory Improvement Amendments (CLIA) certified, College of American Pathologists (CAP) accredited, high-complexity clinical diagnostic laboratory company that provides proprietary Next Generation Sequencing (NGS) genetic testing and diagnostic laboratory services for a wide variety of medical specialties, including cardiology, oncology, immunology, neurology, reproductive health and pharmacogenomics.

Artemis DNA’s testing enhances the delivery of “personalized medicine” by assessing a patient’s own genetic makeup and clinical characteristics which allows for informed decision making in prevention and treatment choices.  Artemis DNA also provides pre- and post-testing genetic education and counseling services, as well as conducting research and development to discover and develop additional novel diagnostic services. 

In June 2022, Artemis DNA announces the closure of its Houston, Texas operations as the company begins a strategic transformation to focus on their business operations and expand their oncology portfolio and testing services in Irvine, California, where the company is headquartered.